Q: What place of service codes and modifiers should be reported on physician claims for wound care services performed via telehealth during the COVID-19 public health emergency?
Q: What are the essential steps when conducting a risk analysis? Are there any sample tools out there to provide guidance on best practices for risk analyses? How often should organizations be conducting these tests?
The Cybersecurity and Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), and HHS released a joint advisory on October 28 to warn healthcare organizations of potential cyberattacks.
The American Medical Association recently released its COVID-19 Physician Practice Financial Impact report, which reveals reductions in patient volume and revenue, as well as higher practice costs during the COVID-19 public health emergency (PHE).
Q: For the purposes of determining a Medicare overpayment, should claims that we are uncertain whether they were appropriate be included? Is this defined under the False Claims Act (FCA)?
Q: CMS created a new MS-DRG for chimeric antigen receptor T-cell (CAR-T) therapies in the fiscal year (FY) 2021 IPPS final rule. Which ICD-10-PCS codes group to this new MS-DRG and does it qualify for an additional new technology add-on payment?
CMS’ Fourth COVID-19 Interim Final Rule with Comment Period includes additional payment for new COVID-19 treatments, price transparency requirements for COVID-19 diagnostic tests, and coverage for potential vaccines among other provisions.
Aetna Life Insurance Company and its affiliated covered entity agreed to pay $1 million to the Office for Civil Rights (OCR) and to adopt a corrective action plan to settle three potential HIPAA violations that occurred in 2017.
